<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>Statistics</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6286F427-1F82-460A-9004-FDA1E7CABDF3"><gtr:id>6286F427-1F82-460A-9004-FDA1E7CABDF3</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>Luise</gtr:otherNames><gtr:surname>Hutton</gtr:surname><gtr:orcidId>0000-0003-0963-9997</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7AAC0F13-7669-495E-8826-6AAE0106F0D4"><gtr:id>7AAC0F13-7669-495E-8826-6AAE0106F0D4</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Guy</gtr:otherNames><gtr:surname>Marson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AF3FBEED-A2F9-45B4-94CF-306E0F03E620"><gtr:id>AF3FBEED-A2F9-45B4-94CF-306E0F03E620</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Copas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400642"><gtr:id>E915ADDA-CA0D-4DDA-ACBE-A8C7AF4C585A</gtr:id><gtr:title>Models for selection bias, applied to controlled trials and observational studies of antiepileptic drugs</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400642</gtr:grantReference><gtr:abstractText>Epilepsy is a common disorder which affects about 3-4% of the populations over a lifetime: it often requires long term drug use. Information on the effectiveness and side effects of drugs is provided by various kinds of studies. It is not easy to combine the information from these different sources, as they refer to different groups of people with epilepsy. For example, response rates for an anti-epileptic drug, (gabapentin) range from 18% in controlled trials to 65% in studies which observed patients before and after they received the drug.

In order to provide reliable summaries across a variety of studies, methods to take into account the difference between patients and studies must be developed. Scientists are studying the issues using a variety of methods. This study concentrates on assessing treatments and side effects and models for the association between how well patients respond in clinical trials, and patients decisions to enter studies.

This research is important for doctors treating people with epilepsy, for managers within the National Health Service, and for scientists working in evidence-based medicine and evidence -based policy. The statistical methods can be used in health, social science and education. 

Summaries of the results about anti-epileptic drugs will be made available through self-help groups, newsletters, doctors and specialist nurses. Summary information with also be available on the web, in association with the Department of Neurological Science at the University of Liverpool.</gtr:abstractText><gtr:technicalSummary>Epilepsy is a common disorder which affects about 3-4% of the population over a lifetime; it often requires long term drug use. Information on the effectiveness and harms of drugs is provided by randomised controlled trials (RCTs), studies following RCTs, in which patients can change to active drug, and before &amp;amp; after observational studies. Response rates are often lower in RCTs than in follow-on and before &amp;amp; after studies (18%, 53% &amp;amp; 65% respectively for gabapentin). Case reports, cohort studies and case-control studies also contribute data on harms, as detecting harms requires data on the effects of long-term use. 

Differentially selected populations raise substantial methodological problems of selection bias which complicate statistical analyses. Patients who enter the follow-on phase are self-selected and not necessarily representative of the main trial. Studies may be samples from different populations, and outcomes may be selectively reported, and published. These selection bias issues occur in many areas of statistics. 

The aim is to develop better ways of assessing treatments and side effects in epilepsy studies, and to extend statistical methodology to cover selection bias problems in the analysis of experimental and observational studies. We will focus on problems relevant to anti-epileptic drugs, where selection bias is evident.

Objectives: 
1. To synthesise information on treatment and side effects of anti-epileptic drugs provided by data from the different kinds of AED studies. 
2. To extend existing work on selection bias to generic problems of differential selection of patients into studies and selection of outcomes.
3. To apply the models of selection bias developed to provide information on drug choice and dosing issues for clinicians, patients and purchasers of care.

People with epilepsy will benefit from better information on the benefits and risks of treatment, and lay leaflets summarising the findings will be used for dissemination. Clinicians and purchasers of care will be able to exploit the enhanced information for design of studies and assessment of treatment effects in chronic diseases, particularly for epilepsy. Statisticians, economists and social scientists will be able to exploit the new methods for investigating selection biases. Pharmaceutical industry will benefit from clarification of effectiveness and harm profiles, enhanced information for design of studies. The market shares of different companies might be variously affected.</gtr:technicalSummary><gtr:fund><gtr:end>2009-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>198554</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EpiPGX</gtr:description><gtr:id>F066BD6D-0327-43C1-AD43-43B309A6F75E</gtr:id><gtr:impact>Software is under development, and analyses will lead to journal articles on epilepsy and genetic variation.</gtr:impact><gtr:outcomeId>5461cc18d41ce5.95494290-3</gtr:outcomeId><gtr:partnerContribution>Discussions of data and possible methods of analysis.</gtr:partnerContribution><gtr:piContribution>I contribute to discussion of research methods, and software developed by my former PhD student, Dr J K Rogers, is being extended by a current PhD student (BCLK) . Initial analyses of data have been provided to the EpiPGX WP02 analysis working group. 

December 2014: further analyses have been provided to the EpiPGx WP02 group, and a day agreed for Professor Hutton and BCLK to discuss the development of statistical models with statisticians from the group.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial College Trust</gtr:department><gtr:description>EpiPGX</gtr:description><gtr:id>A90C65AC-F4B0-4A67-9989-0021C5A1C883</gtr:id><gtr:impact>Software is under development, and analyses will lead to journal articles on epilepsy and genetic variation.</gtr:impact><gtr:outcomeId>5461cc18d41ce5.95494290-1</gtr:outcomeId><gtr:partnerContribution>Discussions of data and possible methods of analysis.</gtr:partnerContribution><gtr:piContribution>I contribute to discussion of research methods, and software developed by my former PhD student, Dr J K Rogers, is being extended by a current PhD student (BCLK) . Initial analyses of data have been provided to the EpiPGX WP02 analysis working group. 

December 2014: further analyses have been provided to the EpiPGx WP02 group, and a day agreed for Professor Hutton and BCLK to discuss the development of statistical models with statisticians from the group.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Health Evaluation and Medical Statistics; University of Liverpool</gtr:department><gtr:description>NIHR Programme Grant</gtr:description><gtr:id>9F904900-4B4C-4591-B4B6-5CF40BF0BE53</gtr:id><gtr:impact>JK Rogers and JL Hutton and AG Marson and DW Chadwick (2012)
Assessing the Risk of Subsequent Tonic-Clonic Seizures in Patients with a History of Simple or Complex Partial Seizures
J of Neurology, Neurosurgery and Psych. 10.1136/jnnp-2011-300917
Disciplines: statistics, neurology

JK Rogers and JL Hutton (2012) Joint modelling of pre-randomisation event counts and multiple post-randomisation survival times with cure rates: application to data for early epilepsy and single seizures J Appl. Stats 10.1080/02664763.2012.748720
Discipline: statistics</gtr:impact><gtr:outcomeId>75A86733A7F-2</gtr:outcomeId><gtr:partnerContribution>Ongoing interaction with epilepsy research, with data and methodological challenges provided for PhD students, motivating further collaboration with statisticians in Lancaster University. Ongoing development of statistical methods, discussions with post-doctoral and other researchers in Liverpool.</gtr:partnerContribution><gtr:piContribution>Statistical methodology, supervising research students and mentoring. 
1. EPSRC funded student worked on analysis of epilepsy data, and development of further statistical models specifically for analysis of epilepsy data. 
2. Conacyt funded student worked on analysis of epilepsy data, and development of further statistical models specifically for analysis of epilepsy data. 
3. Metoring of two post-doctoral research fellows.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EpiPGX</gtr:description><gtr:id>7141601D-50F7-4E5C-8E97-E1E93ADBAD90</gtr:id><gtr:impact>Software is under development, and analyses will lead to journal articles on epilepsy and genetic variation.</gtr:impact><gtr:outcomeId>5461cc18d41ce5.95494290-2</gtr:outcomeId><gtr:partnerContribution>Discussions of data and possible methods of analysis.</gtr:partnerContribution><gtr:piContribution>I contribute to discussion of research methods, and software developed by my former PhD student, Dr J K Rogers, is being extended by a current PhD student (BCLK) . Initial analyses of data have been provided to the EpiPGX WP02 analysis working group. 

December 2014: further analyses have been provided to the EpiPGx WP02 group, and a day agreed for Professor Hutton and BCLK to discuss the development of statistical models with statisticians from the group.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Neurological Science</gtr:department><gtr:description>NIHR Programme Grant</gtr:description><gtr:id>AD2845D6-4EFE-42D3-88D0-CEF4FAB4FE3A</gtr:id><gtr:impact>JK Rogers and JL Hutton and AG Marson and DW Chadwick (2012)
Assessing the Risk of Subsequent Tonic-Clonic Seizures in Patients with a History of Simple or Complex Partial Seizures
J of Neurology, Neurosurgery and Psych. 10.1136/jnnp-2011-300917
Disciplines: statistics, neurology

JK Rogers and JL Hutton (2012) Joint modelling of pre-randomisation event counts and multiple post-randomisation survival times with cure rates: application to data for early epilepsy and single seizures J Appl. Stats 10.1080/02664763.2012.748720
Discipline: statistics</gtr:impact><gtr:outcomeId>75A86733A7F-1</gtr:outcomeId><gtr:partnerContribution>Ongoing interaction with epilepsy research, with data and methodological challenges provided for PhD students, motivating further collaboration with statisticians in Lancaster University. Ongoing development of statistical methods, discussions with post-doctoral and other researchers in Liverpool.</gtr:partnerContribution><gtr:piContribution>Statistical methodology, supervising research students and mentoring. 
1. EPSRC funded student worked on analysis of epilepsy data, and development of further statistical models specifically for analysis of epilepsy data. 
2. Conacyt funded student worked on analysis of epilepsy data, and development of further statistical models specifically for analysis of epilepsy data. 
3. Metoring of two post-doctoral research fellows.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Poster presentations 2007</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AFBA725B-FDB0-46C3-8D91-35053CBB6528</gtr:id><gtr:impact>Conference presentations; Maguire, M.J., Hemming, K., Hutton, J.L., Marson, A.G., 2007. Interpreting efficacy outcomes from open-label extension studies of anti-epileptic drugs. American Epilepsy Society Conference Proceedings Epilepsia Philadelphia, P3.174.

Dissemination and critical review of work by peers</gtr:impact><gtr:outcomeId>537D7C70D7D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster presentations 2008</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6282A48B-2D7F-4849-80F0-F92F1DFFE707</gtr:id><gtr:impact>Conference presentations; Maguire, M.J., Hemming, K., Hutton, J.L., Marson, A.G., 2008. Prevalence of visual field defects following exposure to vigabatrin: A systematic review. 8th European Congress on Epileptology, Berlin. Maguire, M.J., Hemming, K., Hutton, J.L., Marson, A.G., 2008. Prevalence of visual field defects following exposure to vigabatrin: A systematic review. Association of British Neurologists Annual Meeting, Aveimore.

Dissemination of work and critical review of work by peers</gtr:impact><gtr:outcomeId>F3844830359</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oral Presentations 2006-2007</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>704DF2FD-270B-4168-ABA3-07A59EFA1986</gtr:id><gtr:impact>Conference platforms; Maguire, M.J., Hemming, K., Hutton, J.L., Marson, A.G., 2006. Observational anti-epileptic studies: Can we trust them? Investigating publication and language bias. North of England Neurological Association meeting: Liversedge Prize presentation, Harrogate. Maguire, M.J., Hemming, K., Hutton, J.L., Marson, A.G., 2007. Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies, ILAE UK Chapter Gower's prize presentation, Southampton. Maguire, M.J., Hemming, K., Hutton, J.L., Marson, A.G., 2007. Reporting and evaluating efficacy outcomes from open-label extension studies of anti-epileptic drugs. XV Cochrane Colloquium conference proceedings, Cochrane collaboration, Brazil, 064/1.

Dissemination and discussion/ feedback on work</gtr:impact><gtr:outcomeId>E468D61A73D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Expert witness, vigabatrin</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>516AAC7C-B831-4B43-93E4-3A48AA4DD595</gtr:id><gtr:impact>Other audience: mainly lawyers. I provided expert witness reports in a large class action case about the association between vigabatrin and visual field constriction. The patients who participated in the class action won compenstation.

I was not allowed to know the size of the settlement, nor whether this case affected other countries. However, a large pharmaceutical company was the defendant, I think it likely that other countries were affected. I was told that it was many millions.</gtr:impact><gtr:outcomeId>86F64ACF33A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits, Kent, Geneva, Lausanne, Cornwall</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>031705BE-0AEE-46D8-92AC-8EC2C3D4BE84</gtr:id><gtr:impact>Talk to motivate students to study statistics, in order to address health and social issues.

Pupils engaged in discussion! The talks given in Switzerland were by invitation, and the invitations have been repeated.</gtr:impact><gtr:outcomeId>8679AAC6DA4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2012,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster Presentations 2006</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>18CF827C-6F88-4913-BA41-BA1675BE2308</gtr:id><gtr:impact>Conference presentations; Maguire, M.J., Hutton, J.L., Marson, A.G., 2006. The impact of including grey and non-English literature on effects estimates from non-randomized anti-epileptic drug studies. Epilepsia ILAE Finland, P189. Maguire, M.J., Hemming, K., Hutton, J.L., Marson, A.G., 2006. Observational anti-epileptic studies: Can we trust them? Investigating publication and language bias. XIV Cochrane Colloquium Conference Proceedings Dublin, P083.

Dissemination and critical review of work</gtr:impact><gtr:outcomeId>90FC5EAE13B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Expert witness, fetal anti-convulsant syndrome</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A32489E5-8404-4516-B750-A7A5C6584D50</gtr:id><gtr:impact>With Dr Hemming, ongoing discussion and written reports on evidence for benefits and risks of anti-convulsant medication for women who are pregnant.

The other experts are from many countries, so I think it likely that other countries will be affected. 
The case was eventually withdrawn.</gtr:impact><gtr:outcomeId>A3BCE450341</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>28260</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Research Methods Opportunity Funding Scheme Application</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>Award Ref: RMOFS 2012/02</gtr:fundingRef><gtr:id>27C1159C-B053-44E0-8047-73B5EC71B879</gtr:id><gtr:outcomeId>p1Fx15G8rbS</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cochrane reviews used as evidence.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Diagnosis and Management of Epilepsy in Adults - A National Clinical Guideline</gtr:guidelineTitle><gtr:id>D20C9349-6478-4F95-A66D-7EEF30BED953</gtr:id><gtr:outcomeId>P6zxkSD7QcX</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Systematic review, detailed infromation on vigabatrin benefits and harms</gtr:description><gtr:id>A398C959-6AC0-4A3D-A4F6-DB782A28D99B</gtr:id><gtr:impact>The data and publications were relevant in a legal case on visual field restriction</gtr:impact><gtr:outcomeId>546201c33234c4.32057671</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Vigabatrin benefits and harms data base</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.liv.ac.uk/translational-medicine/research/epilepsy</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Methods for Meta-regression with partial information on summary trial or patient characteristics</gtr:description><gtr:id>D80BCCCE-FF4F-4F28-B0D8-4ADB8964B89F</gtr:id><gtr:impact>Cited in ten articles (excluding citation by Hemming).</gtr:impact><gtr:outcomeId>5462012bca93e7.88096431</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Meta-regression with  partial information</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:url>http://onlinelibrary.wiley.com/doi/10.1002/sim.3848/pdf</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4D54D913-6F0A-4ACE-B8AE-C678C8DD0AD8</gtr:id><gtr:title>Assessing the risk of subsequent tonic-clonic seizures in patients with a history of simple or complex partial seizures.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c880c934fa79f1772bcc1713e6f633df"><gtr:id>c880c934fa79f1772bcc1713e6f633df</gtr:id><gtr:otherNames>Rogers JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5460f4af52aaf2.69800399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3780F943-FC44-4B5D-8BC0-51AB486D108C</gtr:id><gtr:title>Intrapartum amnioinfusion for meconium-stained amniotic fluid: evidence for small study effect bias?</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn><gtr:outcomeId>72775DF877A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3294EC4-0869-43A1-8B45-CE7320E3EAD4</gtr:id><gtr:title>Children with cerebral palsy: severity and trends over time.</gtr:title><gtr:parentPublicationTitle>Paediatric and perinatal epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/139da89cfa9a1ccdd84d48a783b59b0a"><gtr:id>139da89cfa9a1ccdd84d48a783b59b0a</gtr:id><gtr:otherNames>Surman G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-5022</gtr:issn><gtr:outcomeId>1C6E6F1033A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D9EB274-6415-4046-872B-3C03C2D6283F</gtr:id><gtr:title>Vigabatrin for refractory partial epilepsy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460f52491a0c6.95715123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D94A4CF6-FD83-4A7C-92AB-433AA656A92B</gtr:id><gtr:title>Differences between European birthweight standards: impact on classification of 'small for gestational age'.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn><gtr:outcomeId>BB351A4A1C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C8F4F8B-E0C0-45C1-9CF2-96894825EC9A</gtr:id><gtr:title>Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies.</gtr:title><gtr:parentPublicationTitle>Epilepsy research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfc69ac4baa364bc59df7fb33e041db"><gtr:id>ebfc69ac4baa364bc59df7fb33e041db</gtr:id><gtr:otherNames>Maguire MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0920-1211</gtr:issn><gtr:outcomeId>1A6EE7D31EE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>500816C2-D38C-4349-A6A6-AF419B85E85D</gtr:id><gtr:title>Vigabatrin for refractory partial epilepsy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>6A78B83A88A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F666DE5-8F0F-4F65-BE81-C5758AAED355</gtr:id><gtr:title>A comparison of customized and population-based birth-weight standards: the influence of gestational age.</gtr:title><gtr:parentPublicationTitle>European journal of obstetrics, gynecology, and reproductive biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0301-2115</gtr:issn><gtr:outcomeId>gjsBED42eFb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB21AEC7-B9A8-482D-B33A-D070EA577CA7</gtr:id><gtr:title>Topiramate add-on for drug-resistant partial epilepsy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6a9e5ad643f9d1e4f58cc2369815813"><gtr:id>e6a9e5ad643f9d1e4f58cc2369815813</gtr:id><gtr:otherNames>Jette N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>0381F3F5A9D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9748B5B6-8E37-4FC3-B664-7AEB51C174C8</gtr:id><gtr:title>The influence of gestational age on severity of impairment in spastic cerebral palsy.</gtr:title><gtr:parentPublicationTitle>The Journal of pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3476</gtr:issn><gtr:outcomeId>E76DB187AED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C83A9E0-67AC-4F66-A06D-20536EFED836</gtr:id><gtr:title>Intrauterine growth and survival in cerebral palsy.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood. Fetal and neonatal edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-2998</gtr:issn><gtr:outcomeId>747E1CF7CC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D28C00BE-CA52-4206-B771-CE625F55A71D</gtr:id><gtr:title>Pregabalin add-on for drug-resistant partial epilepsy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c5906e4de7786a6474b5552995b9472"><gtr:id>2c5906e4de7786a6474b5552995b9472</gtr:id><gtr:otherNames>Lozsadi D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>9AA1CA269D8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC9EDF81-EEFA-4C57-B703-AEA7888C1D64</gtr:id><gtr:title>Fetal growth and birthweight standards as screening tools: methods for evaluating performance.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn><gtr:outcomeId>XZXwRrmSAzK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A932A84F-370D-4EAF-8482-E0FF7723E1AF</gtr:id><gtr:title>Reporting and analysis of open-label extension studies of anti-epileptic drugs.</gtr:title><gtr:parentPublicationTitle>Epilepsy research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfc69ac4baa364bc59df7fb33e041db"><gtr:id>ebfc69ac4baa364bc59df7fb33e041db</gtr:id><gtr:otherNames>Maguire MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0920-1211</gtr:issn><gtr:outcomeId>6F7664D70F2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C1F820F-2C89-4B03-AC01-9C80652A6804</gtr:id><gtr:title>Open label extension studies and patient selection biases.</gtr:title><gtr:parentPublicationTitle>Journal of evaluation in clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1356-1294</gtr:issn><gtr:outcomeId>AB87108A272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BC4AD8F-51E5-4C64-A79B-45ECBF75867A</gtr:id><gtr:title>Joint modelling of pre-randomisation event counts and multiple post-randomisation survival times with cure rates: application to data for early epilepsy and single seizures</gtr:title><gtr:parentPublicationTitle>Journal of Applied Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3319186e5b2b78afe0a4c18dac384546"><gtr:id>3319186e5b2b78afe0a4c18dac384546</gtr:id><gtr:otherNames>Rogers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5460f3d76a2ce7.93331513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7695A30-C569-4687-9C2A-59006CE1BF2C</gtr:id><gtr:title>Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfc69ac4baa364bc59df7fb33e041db"><gtr:id>ebfc69ac4baa364bc59df7fb33e041db</gtr:id><gtr:otherNames>Maguire MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>ELN1HZYsdyq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59EECD7A-67EA-459E-A51C-5F1A016DA1CC</gtr:id><gtr:title>Long-term survival for a cohort of adults with cerebral palsy.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn><gtr:outcomeId>10221682E8D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06447128-C869-40C9-B0C1-2769D79ED6FC</gtr:id><gtr:title>Meta-regression with partial information on summary trial or patient characteristics.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>rQbp98kDMgv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7554E7CA-B9EE-46DC-A210-16BEAD2D3555</gtr:id><gtr:title>Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc8923ab18f27933d5d88f54fec0c0bd"><gtr:id>bc8923ab18f27933d5d88f54fec0c0bd</gtr:id><gtr:otherNames>Mbizvo GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460f4af78c858.69912674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>039F2542-F23F-4BCF-9190-014BA681D981</gtr:id><gtr:title>UKCP: a collaborative network of cerebral palsy registers in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Journal of public health (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/139da89cfa9a1ccdd84d48a783b59b0a"><gtr:id>139da89cfa9a1ccdd84d48a783b59b0a</gtr:id><gtr:otherNames>Surman G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1741-3842</gtr:issn><gtr:outcomeId>0493549927D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAC1BEBA-8C3D-46AE-B1F4-782AA827FF88</gtr:id><gtr:title>Topiramate add-on for drug-resistant partial epilepsy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21627d987a683b91bf50342e6d6ecadf"><gtr:id>21627d987a683b91bf50342e6d6ecadf</gtr:id><gtr:otherNames>Pulman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>56dda1af81c546.23194778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A005B6DB-1304-42CF-83EC-409C770BCDD9</gtr:id><gtr:title>The adverse effects profile of levetiracetam in epilepsy: a more detailed look.</gtr:title><gtr:parentPublicationTitle>The International journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc8923ab18f27933d5d88f54fec0c0bd"><gtr:id>bc8923ab18f27933d5d88f54fec0c0bd</gtr:id><gtr:otherNames>Mbizvo GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0020-7454</gtr:issn><gtr:outcomeId>5460f524e19022.87988267</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1BF7CCD-9C85-4E55-9B9A-61C53C59E140</gtr:id><gtr:title>Tiagabine add-on for drug-resistant partial epilepsy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21627d987a683b91bf50342e6d6ecadf"><gtr:id>21627d987a683b91bf50342e6d6ecadf</gtr:id><gtr:otherNames>Pulman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460f4af2719a7.64100017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD2ABE2D-245E-4937-823B-D1ED60BEE52C</gtr:id><gtr:title>Bayesian sensitivity models for missing covariates in the analysis of survival data.</gtr:title><gtr:parentPublicationTitle>Journal of evaluation in clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac41f57d8ad418dbe4e222256c23dd5"><gtr:id>3ac41f57d8ad418dbe4e222256c23dd5</gtr:id><gtr:otherNames>Hemming K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1356-1294</gtr:issn><gtr:outcomeId>J2XsjCBMgfr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22A93ACF-2E78-4CE3-A41D-82166A9FAA8B</gtr:id><gtr:title>Gabapentin add-on for drug-resistant partial epilepsy.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b57098bfbb5d46311f5cf2667486f3c0"><gtr:id>b57098bfbb5d46311f5cf2667486f3c0</gtr:id><gtr:otherNames>Al-Bachari S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5460f524ba21c8.76575012</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400642</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>B7F5A9CA-62C7-4E68-A2B2-3D6CCA85E16B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>7.3  Management and decision making</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>